Tirzepatide (Mounjaro®) by Eli Lilly is a dual-acting GIP/GLP-1 receptor agonist that has redefined Type 2 Diabetes (T2D) management since its FDA approval in 2022. It surpasses traditional GLP-1 therapies with substantial HbA1c and weight reductions, as seen in the SURPASS-4 trial. Its unique dual mechanism lowers mortality, offering a safe, effective alternative in complex metabolic disorders. With its well-tolerated profile, Tirzepatide is not only transformative for T2D but may also benefit related conditions, potentially including obesity and metabolic comorbidities in future studies.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Beljaro by Beligas Pharmaceuticals, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
